BioCina Announces Appointment of Dr. Thomas Broudy as Chief Executive Officer

BioCina, a leading pharmaceutical contract development and manufacturing organization (CDMO), announced that Dr. Thomas Broudy has been appointed as Chief Executive Officer to lead the company's growth of its biologic drug substance and sterile drug product development and manufacturing services.

"BioCina is entering an exciting new chapter," said Dr. Masood Tayebi, Co-Founder and CEO of Bridgewest Group. "Tommy's deep understanding of our business, his global industry experience, and his proven track record of leadership make him the right person to guide BioCina's continued growth and innovation. The Board has full confidence in his ability to build on the strong foundation we have established and lead the company into its next phase."

Dr. Broudy added, "I am honored to lead BioCina and continue advancing our mission to deliver world-class CDMO services. BioCina's talented team, scientific excellence, and client-centric focus position us to grow as a trusted global CDMO partner. I look forward to working closely with our employees, clients, and stakeholders as we pursue this next phase of growth."